TRAW Insider Trading
Insider Ownership Percentage: 14.00%
Insider Buying (Last 12 Months): $998,207.43
Insider Selling (Last 12 Months): $0.00
Traws Pharma Share Price & Price History
Current Price: $1.21
Price Change: ▲ Price Increase of +0.07 (6.14%)
As of 04/28/2026 05:00 PM ET
Traws Pharma Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2026 | Orbimed Advisors Llc | Major Shareholder | Buy | 597,729 | $1.67 | $998,207.43 | 1,203,250 |  |
Traws Pharma Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/26/2026 | Seven Fleet Capital Management LP | 49,260 | $56K | 0.0% | N/A | 0.617% |  |
| 2/18/2026 | XTX Topco Ltd | 42,210 | $48K | 0.0% | +294.2% | 0.528% | |
| 2/18/2026 | Ikarian Capital LLC | 678,142 | $0.77M | 0.1% | +2,280.0% | 8.486% | |
| 2/18/2026 | Squadron Capital Management LLC | 713,540 | $0.81M | 0.3% | N/A | 8.929% | |
| 2/18/2026 | Boothbay Fund Management LLC | 194,536 | $0.22M | 0.0% | N/A | 2.434% | |
| 2/17/2026 | ADAR1 Capital Management LLC | 154,431 | $0.18M | 0.0% | N/A | 1.933% | |
| 2/17/2026 | Adage Capital Partners GP L.L.C. | 730,000 | $0.83M | 0.0% | +121.2% | 9.136% | |
| 2/13/2026 | State Street Corp | 25,802 | $29K | 0.0% | N/A | 0.323% | |
| 2/9/2026 | Geode Capital Management LLC | 61,653 | $70K | 0.0% | +41.9% | 0.772% | |
| 11/14/2025 | Two Sigma Investments LP | 22,018 | $41K | 0.0% | +37.1% | 0.309% | |
| 5/16/2025 | Alyeska Investment Group L.P. | 52,630 | $0.12M | 0.0% | -54.9% | 0.987% | |
| 5/16/2025 | Adage Capital Partners GP L.L.C. | 330,000 | $0.76M | 0.0% | N/A | 6.187% | |
| 5/15/2025 | Vestal Point Capital LP | 175,000 | $0.40M | 0.0% | +133.3% | 3.281% | |
| 2/17/2025 | Vestal Point Capital LP | 75,000 | $0.67M | 0.0% | N/A | 2.055% | |
| 2/17/2025 | Millennium Management LLC | 10,012 | $89K | 0.0% | N/A | 0.274% | |
| 2/17/2025 | Alyeska Investment Group L.P. | 116,714 | $1.04M | 0.0% | N/A | 3.198% | |
| 2/14/2025 | Boothbay Fund Management LLC | 28,431 | $0.25M | 0.0% | N/A | 0.779% | |
| 2/13/2025 | Renaissance Technologies LLC | 10,052 | $89K | 0.0% | N/A | 0.275% | |
| 2/12/2025 | Geode Capital Management LLC | 20,801 | $0.19M | 0.0% | N/A | 0.570% | |
Data available starting January 2016
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Read More on Traws Pharma
Volume
88,306 shs
Average Volume
236,593 shs
Market Capitalization
$12.29 million
P/E Ratio
1.30
Dividend Yield
N/A
Beta
1.61
Who are the company insiders with the largest holdings of Traws Pharma?
